DIANEAL PD-2 with Dextrose is a Intraperitoneal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Baxter Healthcare Corporation. The primary component is Calcium Chloride; Dextrose Monohydrate; Magnesium Chloride; Sodium Chloride; Sodium Lactate.
| Product ID | 0941-0411_1bac9069-af32-4e88-9d96-bf4006f0729f |
| NDC | 0941-0411 |
| Product Type | Human Prescription Drug |
| Proprietary Name | DIANEAL PD-2 with Dextrose |
| Generic Name | Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRAPERITONEAL |
| Marketing Start Date | 1978-09-27 |
| Marketing Category | NDA / NDA |
| Application Number | NDA017512 |
| Labeler Name | Baxter Healthcare Corporation |
| Substance Name | CALCIUM CHLORIDE; DEXTROSE MONOHYDRATE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE |
| Active Ingredient Strength | 26 mg/100mL; g/100mL; mg/100mL; mg/100mL; mg/100mL |
| Pharm Classes | Blood Coagulation Factor [EPC], Calcium [CS], Calculi Dissolution Agent [EPC], Cations, Divalent [CS], Increased Coagulation Factor Activity [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Magnesium Ion Exchange Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Activity [MoA], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Osmotic Laxative [EPC], Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 1978-09-27 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2004-11-30 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2009-12-31 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2013-02-28 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2009-11-30 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2004-11-30 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2015-02-18 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2009-12-31 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2013-03-31 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2004-11-30 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2012-10-31 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 1978-09-27 |
| Marketing Category | NDA |
| Application Number | NDA017512 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1978-09-27 |
| Marketing End Date | 2009-12-31 |
| Ingredient | Strength |
|---|---|
| DEXTROSE MONOHYDRATE | 1.5 g/100mL |
| SPL SET ID: | aa268d3f-7389-4f25-801f-5d4825495f08 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0941-0411 | DIANEAL PD-2 with Dextrose | sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose |
| 0941-0413 | DIANEAL PD-2 with Dextrose | sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose |
| 0941-0415 | DIANEAL PD-2 with Dextrose | sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose |
| 0941-0429 | DIANEAL PD-2 with Dextrose | DIANEAL PD-2 with Dextrose |
| 0941-0427 | DIANEAL PD-2 with Dextrose | DIANEAL PD-2 with Dextrose |
| 0941-0426 | DIANEAL PD-2 with Dextrose | DIANEAL PD-2 with Dextrose |
| 0941-0409 | DIANEAL Low Calcium with Dextrose | sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose |
| 0941-0424 | DIANEAL Low Calcium with Dextrose | sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose |